IQVIA data puts Oral Wegovy at about 173,500 weekly scripts, still double Lilly's Foundayo at the same launch stage. Novo also eyes 15% to 20% yearly GLP-1 growth in India.
Recap by typeshit. Post by X on X.
Lilly's tirzepatide shot Zepbound now has FDA approval in a KwikPen format for weight management. Tap through for details on the new pen.
At the SIO congress in Palermo, specialists flagged short real-world adherence and no national reimbursement in Italy. Oral semaglutide and orforglipron are expected there in 2027.
Polish pharmacy platform GdziePoLek says, citing the manufacturer, that the first Oral Wegovy shipment should arrive soon. No exact launch date is set yet.
A short clip from Dr. Reese pushing back on the rush toward peptides as an easy shortcut, with little detail beyond that.
19:08
A physician on YouTube makes the case that GLP-1 drugs like Ozempic and Mounjaro, plus trial drug retatrutide, are misunderstood when framed as weight loss drugs.
Icotrokinra became the first approved oral IL23 receptor blocker, and a trial found tirzepatide plus ixekizumab gave deeper responses.
Loading…